pdf (brief report)
To download the full report and to find additional resources, visit
Ovarian Cancers: Evolving Paradigms
in Research and Care gives a broad overview of the state of the science in
ovarian cancer research, highlights major knowledge gaps, and provides
recommendations to help reduce the incidence of and morbidity and mortality
from ovarian cancers by focusing on promising research themes that could
advance risk prediction, prevention, early detection, comprehensive care, and
cure. The committee focused on identifying the research gaps that, if
addressed, could have the greatest impact on reducing morbidity or mortality.
The committee identified four
overarching concepts that should be applied to each recommendation in this
report:
• As the most common and lethal
subtype, the study of high-grade serous carcinomas needs to be given priority.
• Even so, more subtype-specific
research is also needed to further define the differences among the various
subtypes;
• Given the relative rarity and
heterogeneity of ovarian cancers, collaborative research (including the pooling
and sharing of data and biospecimen resources, such as through consortia) is
essential; and
• The dissemination of new knowledge
and the implementation of evidence-based interventions and practices are the final
steps in the knowledge translation process.
A wide variety of stakeholders are
integral to ovarian cancer research, including the U.S. Congress, federal
agencies (e.g., the Centers for Disease Control and Prevention, Department of
Defense, Food and Drug Administration, National Institutes of Health), private
foundations, industry, academic institutions, professional societies, and advocacy
groups. Most of these stakeholders are engaged in research across the care
continuum, and many are both funders and performers of research. The committee
therefore concluded that directing research toward the gaps identified in the recommendations
is the responsibility of all stakeholders in their individual and collaborative
efforts to fund, perform, or advocate for ovarian cancer research.
The following recommendations are
intertwined and so need to be considered simultaneously, not sequentially.
Their sequence should not be considered as priority of importance or order of
implementation. (11).....
